A Quiet Breakthrough at ADA 2026: New Therapy Could Fill Gap for Patients Who Can’t Use GLP-1 Drugs

Petrelintide emerged as a major ADA 2026 breakthrough, offering hope for patients who stop GLP-1 therapies due to nausea and GI side effects.

Have A Referral?